BRCA1 and breast carcinoma: SERPINA3 is expressed at higher level in epithelial cells of BRCA1 and BRCA2 mutation carriers compared with non-carrier (Supplementary Fig. S1); this has previously been shown to confer invasiveness and epithelial-to-mesenchymal transition (EMT) phenotype to breast cancer cells (28).